Results 181 to 190 of about 10,236,148 (357)

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C. Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo, Matthew Appleby, Phil Woodgate, Seema Maru, Patricia Limousin, Christine Girges, Thomas Foltynie, Stephane Palfi, Roger A. Barker   +19 more
wiley   +1 more source

Detection and quantification of cyclo-dopa amides in Portulaca oleracea L. by HPLC-DAD and HPLC-ESI-MS/MS

, 2014
Ze‐Zhao Jiao, Lan Xiang
openalex   +1 more source

Assessment of pharmacokinetic interaction of L-dopa and benserazide : animal model, mechanistic mathematical models, and allometric scaling across species [PDF]

, 2004
Grange, Susanna Sarah
core   +1 more source

Sex and Diet Biased Effect of L-DOPA on Iron Accumulation in the Ventral Midbrain. [PDF]

J Neurochem
Serpa RO, Tufano E, Palsa K, Helmuth TB, Mills-Huffnagle S, Kant M, Connor JR.   +6 more
europepmc   +1 more source

High speed memory scanning in Parkinson's disease: Effects of L-Dopa [PDF]

, 1989
Werner Poewe, T. Benke, W. Berger, Ludwig Schelosky   +3 more
openalex   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

Dopamine 2 receptor ablation from cholinergic neurons attenuates L-DOPA induced dyskinesias. [PDF]

Front Aging Neurosci
Uribe-Cano S, Malave L, Kottmann AH.
europepmc   +1 more source

Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion

Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley   +1 more source

A Phase 1 Study of Convection‐Enhanced Delivery of Intraputaminal AAV2‐GDNF in Advanced Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is a progressive neurodegenerative disorder. Neurotrophic therapeutic approaches have been limited in part by incomplete delivery to the putamen. We developed image‐guided convection‐enhanced delivery with real‐time monitoring to improve intraputaminal distribution of neurotrophic gene therapy. Objectives To
John D. Heiss, Debra J. Ehrlich, Codrin Lungu, Joseph Y. Choi, Gretchen Scott, Irene Dustin, Dima A. Hammoud, Peter Herscovitch, Russell R. Lonser, Kareem A. Zaghloul, Krystof Bankiewicz   +10 more
wiley   +1 more source

No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician's Point of View. [PDF]

Neurol Int
Müller T.
europepmc   +1 more source